Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).
Haddad R, Seiwert T, Chow L, Gupta S, Weiss J, Gluck I, Eder J, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Huang L, Ayers M, Mogg R, Cristescu R, Cheng J, Mehra R. Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2017, 35: 6009-6009. DOI: 10.1200/jco.2017.35.15_suppl.6009.Peer-Reviewed Original ResearchNeoantigen loadWhole-exome sequencingPD-1/EBV statusObjective responseGene expression profilesNeck squamous cell carcinomaAnti CTLA-4PD-1 therapyIndependent predictive valueSquamous cell carcinomaCentral immune toleranceMutational loadFFPE tumor specimensSomatic mutational loadGEP scoreL1 immunotherapyL1 therapyClinical outcomesImmune toleranceSelect tumorsCell carcinomaCTLA-4Combined cohortViral status